All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.
Juan BerenguerÁngela Gil-MartinInmaculada JarrinAna MorenoLourdes DominguezMarisa MontesTeresa Aldámiz-EchevarríaMaría J TéllezIgnacio SantosLaura BenitezJosé SanzPablo RyanGabriel GasparBeatriz AlvarezJuan E LosaRafael Torres-PereaCarlos BarrosJuan V San MartinSari ArponenMaría T de GuzmánRaquel MonsalvoAna VegasMaría T Garcia-BenayasRegino SerranoLuis GotuzzoMaría Antonia MenendezLuis M BeldaEduardo MalmiercaMaría J CalvoEncarnación Cruz-MartosJuan J González-GarcíaPublished in: Hepatology (Baltimore, Md.) (2018)
In this large real-world study, direct-acting antiviral agent-based therapy was safe and highly effective in coinfected patients; predictors of failure included gender, human immunodeficiency virus-related immunosuppression, HCV RNA load, severity of liver disease, and the use of suboptimal direct-acting antiviral agent-based regimens. (Hepatology 2018;68:32-47).